4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Recognising Adverse Drug Reactions (WEB-RADR)
Date du début: 1 sept. 2014, Date de fin: 31 août 2017,
WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Voir le projet
20
Participants partenaires
TERMINÉ
The potential of human kidney stem/progenitor cells for use in drug discovery and regenerative therapy programmes (NEPHROTOOLS)
Date du début: 1 déc. 2011, Date de fin: 30 nov. 2015,
Renal disease is a global public health problem, with the incidence of end stage renal disease (ESRD) rising annually. Current treatment options for ESRD are dialysis or renal transplantation, which have significant drawbacks in terms of increased morbidity and mortality, besides placing an increasing economic burden on society. The development of interventions aimed at preventing ESRD, including ...
Voir le projet
11
Participants partenaires
TERMINÉ
Buffet Control of Transonic Wings (BUCOLIC)
Date du début: 1 oct. 2013, Date de fin: 30 juin 2015,
"The aim of this work programme is to develop a capability to understand and predict transonic buffet on wings fitted with buffet control devices.Wind tunnel tests will be performed on a half model with buffet control devices fitted to measure dynamic flow characteristics during buffet onset.Unsteady RANS and DES CFD calculations will be carried out, validated against the wind tunnel data. The CF ...
Voir le projet
2
Participants partenaires
TERMINÉ
Modelling and predicting sensitivity to targeted therapies in colorectal cancers (COLTHERES)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,
Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk ...
Voir le projet